PARP inhibitors in Prostate Cancer
PARP inhibitors in Prostate Cancer
GU CONNECT has developed a comprehensive resource which is available on ESMO OncologyPRO, providing information on PARP inhibitors in prostate cancer GU CONNECT has developed a comprehensive resource which is available on ESMO OncologyPRO, providing information on PARP inhibitors in prostate cancerDr. Elena Castro, Dr. Alexander Wyatt, Prof. Gerhardt Attard, Prof. Steven Joniau
Visit the resource on ESMO OncologyPRO
Dr. Elena Castro
Medical Oncologist
Hospital Universitario Virgen de la Victoria
Spain
Dr. Alexander Wyatt
GU Cancer Genomics Expert
Vancouver Prostate Centre, University of British Columbia
Canada
Prof. Gerhardt Attard
Medical Oncologist
University College London Cancer Institute
United Kingdom (UK)
Prof. Steven Joniau
Urologist
University Hospital Leuven
Belgium
| 
30 min
|
Sep 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
PARP inhibitors in Prostate Cancer
This material has been developed as a resource providing information on poly (ADP-ribose) polymerase (PARP) inhibitors in prostate cancer.
The information included in this material is compiled from a review of the medical literature and expert guidance from Elena Castro (medical oncologist), Alexander Wyatt (GU cancer genomics expert), Gerhardt Attard (medical oncologist) and Steven Joniau (urologist).
The resource covers the following topics:
- The mechanism of action of PARP inhibition and its role in the treatment of prostate cancer
- Testing strategies to identify DNA Damage Repair (DDR) mutations in prostate cancer, and their prevalence and clinical relevance
- How to perform genetic counselling
- The difference between different genomic tests
- Clinical efficacy and safety profile of PARP inhibitors for patients with prostate cancer
- Patient selection using genetic/genomic testing results
- The management of adverse events
- The place of PARP inhibition in the prostate cancer treatment pathway and future developments
- The PARP inhibitors in development for prostate cancer
- The potential combination strategies with PARP inhibitors
COR2ED have donated this content to ESMO to reflect that personalised precision medicine is new for most healthcare professionals treating patients with prostate cancer and that there is a need to provide consensus and practical guidance on this topic.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
28 min
Other programmes developed by Dr. Elena Castro
Dr. Elena Castro
Medical Oncologist
Hospital Universitario Virgen de la Victoria
Spain
Other programmes developed by Prof. Gerhardt Attard
Prof. Gerhardt Attard
Medical Oncologist
University College London Cancer Institute
United Kingdom (UK)
Other programmes developed by Prof. Steven Joniau
Prof. Steven Joniau
Urologist
University Hospital Leuven
Belgium
